These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 1780754

  • 1. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine.
    Capizzi RL, White JC, Powell BL, Perrino F.
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):54-69. PubMed ID: 1780754
    [Abstract] [Full Text] [Related]

  • 2. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B, Capizzi RL, Kute TE, Morgan T, Dimling J.
    Cancer Res; 1989 Jun 15; 49(12):3259-66. PubMed ID: 2720678
    [Abstract] [Full Text] [Related]

  • 3. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 4. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.
    Cancer Chemother Pharmacol; 2007 May 01; 59(6):771-9. PubMed ID: 17256136
    [Abstract] [Full Text] [Related]

  • 5. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [Abstract] [Full Text] [Related]

  • 6. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb 15; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 7. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W, Nowak B, Keating MJ.
    Cancer Treat Rep; 1987 May 15; 71(5):479-83. PubMed ID: 3567973
    [Abstract] [Full Text] [Related]

  • 8. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI, Powell W.
    Cancer Invest; 1987 May 15; 5(4):293-9. PubMed ID: 3664332
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF, Huang P, Plunkett W, Gandhi V.
    Clin Cancer Res; 1996 Apr 15; 2(4):653-8. PubMed ID: 9816215
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system.
    Raymakers RA, Slocum HK, Minderman H, Malmberg M, Rustum YM.
    Exp Hematol; 1993 May 15; 21(5):602-7. PubMed ID: 8513859
    [Abstract] [Full Text] [Related]

  • 14. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO, Plunkett W, Dixon DO.
    Cancer Res; 1985 Nov 15; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [Abstract] [Full Text] [Related]

  • 15. Deoxyguanosine enhancement of cytarabine nucleotide accumulation in human leukemia cells.
    Akman SA, Ross DD, Joneckis CC, Fox BM, Bachur NR.
    Cancer Treat Rep; 1985 Nov 15; 69(7-8):851-7. PubMed ID: 4016794
    [Abstract] [Full Text] [Related]

  • 16. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
    Ueda T, Kamiya K, Urasaki Y, Wataya S, Kawai Y, Tsutani H, Sugiyama M, Nakamura T.
    Cancer Res; 1994 Jan 01; 54(1):109-13. PubMed ID: 8261429
    [Abstract] [Full Text] [Related]

  • 17. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S.
    Clin Cancer Res; 2002 Jul 01; 8(7):2123-33. PubMed ID: 12114412
    [Abstract] [Full Text] [Related]

  • 18. [Is the pharmacokinetic profile of cytarabine clinically relevant?].
    Boos J.
    Klin Padiatr; 1992 Jul 01; 204(4):198-203. PubMed ID: 1518256
    [Abstract] [Full Text] [Related]

  • 19. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
    Damon LE, Plunkett W, Linker CA.
    Cancer Res; 1991 Aug 15; 51(16):4141-5. PubMed ID: 1868435
    [Abstract] [Full Text] [Related]

  • 20. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI, Weinberg KI, Sato JK, Lenarsky C, Willoughby ML, Coates TD, Ozkaynak MF, Parkman R.
    Cancer Res; 1989 Jan 01; 49(1):241-7. PubMed ID: 2908850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.